Oct 25, 2008

NATCO Pharma launches its first nano - technology drug - Albupax

19 Sep 2008 | 11:11


Investor Forums- http://forums.investorline.co.in/

NATCO Pharma launches its first nano - technology drug - Albupax


Hyderabad based NATCO Pharma has launched its first nano - technology
drug - Albupax. Albupax is the first generic version of the
international brand - Abraxane - (2007 sales approximately US$ 375
million) of Abraxis Bio-sciences, USA.

Albupax,
which is the brand name of NATCO consists of Paclitaxel in an Albumin
bound nano-particle form. Albupax is used in the treatment of breast
cancer. The incidence of breast cancer is on the rise in India, and
currently over a lakh new patients are added every year. By 2015, the
number of new cases are likely to go upto 2 lakh every year.

Albupax
replaces the conventional Paclitaxel and has the advantage of having
least side effects. In the conventional Paclitaxel, the solvent
polyethylated castor oil is used, which causes severe side effects such
as neutropenia, hyper - sensitivity reactions and neuropathy. Albupax
does not contain this solvent, and hence can be given in optimum doses
for enhanced efficacy. Albupax has been indigenously developed by NATCO
in India and is the first albumin bound Paclitaxel in nano-particle to
be developed in India.

Each 100 mg vial of Albupax has been
affordably priced at Rs 11,500. The estimated Indian market for this
product is in the region of Rs 150 crore and NATCO expects Albupax to
garner a reasonable share of this market. NATCO believes that Albupax
has the potential of becoming the single largest brand amongst its
basket of oncology products. NATCO is also exploring the possibility of
a tie-up for taking this brand to international markets.

The company made this announcement during the trading hours today, 19 September 2008.

0 comments: